Neptune Krill Oil Demonstrates Positive Economic Benefit
for Cholesterol Treatment
The economic model for the analysis was based on the 10-year risk for cardiovascular disease as estimated by the Framingham model. According to this model, an individual’s 10-year risk for a cardiovascular event is a function of age, gender, systolic blood pressure, TC, HDL-C, smoking status and presence of left ventricular hypertrophy as detected by an electrocardiogram. The model is based on a logistic regression analysis derived on a cohort of over 5,000 patients that have been followed for 40 years or more.
The Framingham model has been shown to be a valid predictor of cardiovascular risk. Therefore, changes in the Framingham-derived risk estimates are considered to represent the change in the individual patient cardiovascular risk that are sensitive to change induced by preventive interventions. The logistic regression parameters are used to estimate the patient’s 10-year risk for having a cardiovascular event.
The results of the study demonstrate the following:
The authors conclude that “The results of this analysis have shown that NKO as monotherapy or given in combination with a statin is efficient and cost-effective in the management of dyslipidemia”. In addition the authors concluded that “The results have important implications for the management of the growing population of patients with dyslipidemia, who require safe and effective treatment and who may not be responsive, nor tolerant, nor appropriate candidates for treatment with a statin alone”
The analysis was conducted between January and August 2007 by a team of renowned researchers: Dr. Keith Worsley MSc., PhD, FRSC and recipient of the Gold Medal, Statistical Society of Canada, affiliated with McGill University of Montreal; Dr. Shahin Jaffer, MD, FRCPC Head, Department of Medicine, Delta Hospital, University of British Columbia; and Dr. A. Shekhar Pandey, B.Sc., MD, FRCPC, ABIM, CBNC, Adult Invasive, Non-invasive, & Preventive Cardiologist, Cambridge Cardiac Care Centre, Cambridge, Ontario.
“Benefit, risk and economic assessments are
now the pivotal points not only for government approval of medicine for
treatment of diseases that require long-term care but are also considered
important factors for the pharmaceutical industry decision makers before
taking over the development of a new drug” stated Dr. Tina Sampalis M.D.,
Ph.D., Vice-President of R&D and Business Development of Neptune. “I am
extremely proud that we have now successfully completed this study that
was an important achievement for the pharmaceutical development of NKO.
With the results of this analysis we have now provided valuable evidence
that NKO reduces cardiovascular risk while remaining cost effective and
even cost minimizing over many years of use.”
7-Keto DHEA -
Ageless Face, Ageless Mind -
Alpha-Lipoic Acid and
Aronia from Chokeberry
- Avemar -
Beta Glucan -
- Bioperine -
Butterbur - Cetyl
Myristoleate (CMO) -
Sun, Yaeyama -
Coconut Oil -
- Curcumin from Turmeric -
Epicor -Fenugreek - French Maritime Pine Tree Bark -
& Chondroitin -
Goji Berry -
Seed Extract -
Green Tea -
- Hoodia -
Human Growth Hormone (HGH) -
Hydrogen (H-): The Fuel of Life -
Krill Oil -
L-Carnitine - L-Carnosine -
Modified Citrus Pectin (MCP)
- Mushrooms -
N-Acetyl Cysteine (NAC) -
Nattokinase - Neptune
Krill Oil -
of Oregano -
Omega-3 - DHA, EPA -
Pepsin GI -
Phosphatidyl Serine (PS) -
- Policosanol -
Inflammation and Weight Loss
- Immune -
Life Force Multiple -
Mercury Cleansing -
Thistle and Liver Disease -
Specials | Product Info |
Old Health News | FAQs |
About us |
Links3 | Sitemap |
Alphabetic Product Listing | Products by Category | Links4 | Links5
TOLL FREE: 800-401-9186
Copyright © 2001-2010, Discount Herbs & Vitamins, Inc. All rights reserved.
These statements have not
been evaluated by the Food and Drug Administration.
These products are not intended to diagnose, treat, cure, or prevent any disease.
Please consult a qualified medical practitioner for medical advice.